or Try an Advanced Search...

    Technical Analysis for KYTX - Kyverna Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 9.84 10.56% 0.94
    KYTX closed up 10.56 percent on Friday, July 26, 2024, on 45 percent of normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent N/A Down Flat
    Historical KYTX trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Multiple of Ten Bearish Other 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Fell Below 20 DMA Bearish 10.56%
    NR7 Range Contraction 10.56%
    NR7-2 Range Contraction 10.56%
    Narrow Range Bar Range Contraction 10.56%
    Wide Bands Range Expansion 10.56%
    Down 3 Days in a Row Weakness 10.56%
    Older End-of-Day Signals for KYTX ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 10 DMA about 8 hours ago
    Up 1 ATR about 8 hours ago
    Up 10% about 8 hours ago
    60 Minute Opening Range Breakout about 12 hours ago
    20 DMA Support about 14 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    KYTX Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Sjögren Syndrome Lupus Nephritis Systemic Sclerosis

    Is KYTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 18 Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
    Jul 16 Kyverna gains after FDA’s RMAT designation for lead asset
    Jul 16 Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate
    Jul 16 Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
    Jul 16 Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday
    Jul 15 Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
    Jul 3 H.C. Wainwright starts Kyverna at neutral, says awaiting more data
    Jun 20 Kyverna gains as FDA clears trial for lead therapy
    Jun 20 Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
    Jun 17 First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
    See more KYTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 35.06
    52 Week Low 6.75
    Average Volume 658,778
    200-Day Moving Average 0.00
    50-Day Moving Average 10.75
    20-Day Moving Average 9.03
    10-Day Moving Average 9.88
    Average True Range 1.04
    RSI (14) 50.74
    ADX 13.53
    +DI 22.53
    -DI 20.86
    Chandelier Exit (Long, 3 ATRs) 8.28
    Chandelier Exit (Short, 3 ATRs) 10.02
    Upper Bollinger Bands 11.30
    Lower Bollinger Band 6.75
    Percent B (%b) 0.68
    BandWidth 50.47
    MACD Line -0.22
    MACD Signal Line -0.40
    MACD Histogram 0.1807
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.64
    Resistance 3 (R3) 11.50 10.75 11.34
    Resistance 2 (R2) 10.75 10.29 10.82 11.24
    Resistance 1 (R1) 10.30 10.01 10.52 10.44 11.14
    Pivot Point 9.55 9.55 9.66 9.62 9.55
    Support 1 (S1) 9.10 9.09 9.32 9.24 8.54
    Support 2 (S2) 8.35 8.81 8.42 8.44
    Support 3 (S3) 7.90 8.35 8.34
    Support 4 (S4) 8.04